Last Updated: July 22, 2026

Litigation Details for Headwater Research LLC v. SAMSUNG ELECTRONICS AMERICA, INC. (E.D. Tex. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Headwater Research LLC v. SAMSUNG ELECTRONICS AMERICA, INC. (E.D. Tex. 2023)

Docket ⤷  Start Trial Date Filed 2023-03-10
Court District Court, E.D. Texas Date Terminated
Cause 35:271 Patent Infringement Assigned To James Rodney Gilstrap
Jury Demand Both Referred To Roy S. Payne
Parties DAVID FOLSOM
Patents 10,124,014; 11,027,031; 11,040,004; 11,040,018; 11,040,029; 11,040,042; 12,005,043; 12,005,069; 8,039,009; 9,000,021; 9,056,052
Attorneys David Aaron Nelson
Firms Quinn Emanuel Urquhart & Sullivan, LLP - LA
Link to Docket External link to docket
Small Molecule Drugs cited in Headwater Research LLC v. SAMSUNG ELECTRONICS AMERICA, INC.

Litigation summary and analysis for: Headwater Research LLC v. SAMSUNG ELECTRONICS AMERICA, INC. (E.D. Tex. 2023)

Last updated: July 7, 2026

Headwater Research LLC v. Samsung Electronics America, Inc. (E.D. Texas 2:23-cv-00103) Litigation Summary and Patent Analysis

Headwater Research LLC sued Samsung Electronics America, Inc. in the U.S. District Court for the Eastern District of Texas under case number 2:23-cv-00103. The docket record needed to produce an accurate patent-by-patent infringement and claim construction analysis, including asserted patent numbers, technology, parties’ identified accused products, claim charts, Markman outcomes, and claim scope outcomes, is not available in the provided material.

Because a complete and accurate litigation summary requires at least the complaint and operative infringement content (asserted patents, independent claim targets, accused functionalities, and any amended pleadings), this response cannot be produced without those core docket facts.

What patents does Headwater Research LLC assert in 2:23-cv-00103 against Samsung?

No asserted patent numbers, publication numbers, or listed claim groupings are provided. Without the complaint or a docket-extracted “Patents-in-Suit” list, a patent estate analysis would be incomplete.

Which Samsung products or features are accused in 2:23-cv-00103?

The accused Samsung devices or features are not provided. A meaningful infringement analysis depends on the specific accused products (models or product categories), technical feature mappings, and complaint allegations.

What claims were asserted, and what claim constructions were adopted in Markman?

Markman dates, orders, and the construed claim terms are not provided. Claim construction outcomes are required to analyze infringement risk by claim scope.

What is the procedural posture in E.D. Texas 2:23-cv-00103 (motions, stay, venue, transfers)?

Key procedural milestones are not provided, including:

  • motion to dismiss status
  • transfer/venue motions
  • discovery sequence and deadlines
  • summary judgment motions
  • trial scheduling and whether the case is stayed

What motions to dismiss or early dispositive motions were filed by Samsung?

Motion titles and grounds are not provided. A defendant’s invalidity, non-infringement, pleading deficiency, or indefiniteness positions cannot be analyzed without filings.

Was there any summary judgment, Daubert, or exclusion order affecting technical or expert testimony?

No evidentiary rulings or orders are provided.

Did the parties reach a settlement or stipulate dismissal in 2:23-cv-00103?

No settlement, consent judgment, or dismissal status is provided.

How does this case affect the broader patent landscape for Samsung device software or hardware?

A landscape impact assessment requires the asserted patents’ technology area, priority chain, remaining enforceable terms, and whether related cases exist across jurisdictions. Those inputs are not provided.

How strong is Headwater’s patent estate in this dispute (validity and enforceability view)?

This requires:

  • asserted patent family identification
  • maintenance status and any reexamination/Inter Partes Review history
  • prosecution history and claim breadth indicators
  • most relevant prior art and obviousness themes raised in litigation

None of that information is provided.


Key Takeaways

  • The case identifier 2:23-cv-00103 and parties are known, but the asserted patents, accused products, pleadings, claim constructions, and dispositive/settlement status are not provided.
  • Without the complaint and operative orders, a litigation summary that is accurate and useful for R&D, licensing, or litigation decision-making cannot be generated.

FAQs

  1. What court and judge is handling Headwater Research LLC v. Samsung Electronics America, Inc., 2:23-cv-00103?
  2. Were any patents-in-suit found invalid or narrowed in claim construction for 2:23-cv-00103?
  3. What accused Samsung product categories are typically implicated in Headwater’s device-related suits in E.D. Texas?
  4. Is 2:23-cv-00103 stayed pending inter partes review or related litigation?
  5. What is the likelihood of generic or design-around freedom if the asserted claims target standard device features?

References (APA)

  1. Headwater Research LLC v. Samsung Electronics America, Inc., No. 2:23-cv-00103 (E.D. Tex.).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.